If your phone or car uses a lithium-ion battery, the company highlighted in today’s article likely manufactured the lithium chemical used in that battery – and with the lithium-ion battery market expected to grow over 100% by 2025, this company’s stock may be set for a massive breakout. For the stock in question – which the author recommends as a buy based on its momentum and quality – CLICK HERE.
The two small-cap biotech stocks highlighted in today’s article appear poised to dominate this year and beyond. Why? As the author explains, “Both companies are pioneers in their respective spaces and offer robust pipelines, with lead products nearing the middle of the drug-development process.” For more on these two under-the-radar biotech stocks – and the science and potential related to their products – CLICK HERE.
The stock market could be in for an especially volatile time this week and into July – and while the acceleration in new coronavirus cases would be a major factor driving that volatility, it would not be the only factor. As the author of today’s article explains, “there are a number of factors that also have the potential to exacerbate volatility in financial markets next week and into July” – and he outlines seven of them. For more, CLICK HERE.
“Shares of smaller companies are often volatile, but for investors willing to ride out the tug-of-war between greed and fear, these companies have strong growth businesses that should pay off for their investors over time, and are good buys now,” advises the author of today’s article, pointing to the fact that small-cap stocks have not recovered as quickly as their large-cap counterparts. For three small-cap stocks that appear to have particularly strong growth prospects, CLICK HERE.
As the retail business highlighted in today’s article has reopened, “Customers have been braving public spaces in droves to visit its brick-and-mortar locations and tear through its deals on off-price designer goods,” observes today’s article. As a result, its stock has staged a recovery – and pent-up demand from “treasure hunting” shoppers could cause it to break out even higher, according to analysts. And with an options play, traders could book even bigger profits. For more, CLICK HERE.
“With the scramble for viral and antibody testing kits, and the ultimate goal of finding a vaccine for Covid-19, many biotech companies are suddenly in the spotlight. Even those that aren’t directly working on a Covid-related solution look more attractive,” observes the author of today’s article, who also singles out biotech stocks as being the one possible bright spot in the current, challenging market environment. For seven biotech stocks he highlights as particularly well positioned for a nice payoff, CLICK HERE.
It should come as no surprise that one of the top biotech stocks to consider right now, as identified by the author of today’s article, is a coronavirus play whose COVID-19 vaccine candidate has just been approved by the FDA for Phase II clinical trials: Moderna. For the author’s other two top picks from the “recession-proof” biotech sector – which he notes could grow to $775 billion by 2024 – CLICK HERE.
While the broader market has been all over the place over the past few months, one area that has performed significantly better than the S&P 500 is the biotech sector. Of course, while promising clinical trial results or regulatory approval of a treatment can serve as the catalyst that sends shares of biotech companies soaring, it’s critical to separate the biotechs poised for massive growth from those destined for failure. Today’s article highlights three biotech stocks that are all Buy-rated, trading under $4 a share, and have at least 50% upside potential. For more, CLICK HERE.
The small-cap biotech highlighted in today’s article has had mixed clinical results when it comes to one of its novel cancer immunotherapy candidates. The author, however, advises that “Despite the uncertainty surrounding [the candidate], investors shouldn’t be dismayed. Usually, when investing in small-cap biotech stocks, what’s far more important in the decision-making process is to see whether the company is backed by institutional investors” – and not only does this firm have institutional backing, but it also has a number of research and development partnerships with big pharma players. For more on this stock that may appeal to biotech investors with a high risk tolerance – CLICK HERE.
After three straight months of losses, April brought the S&P 500 health care sector its best one-month gain in twenty years, and today’s article notes that “The sector’s top performing stocks were diagnostic firms at the heart of the Covid-19 testing expansion.” Moreover, the biotech sector outpaced both the health care sector and the overall market, again with Covid-related biotech stocks being among the best performers. For more on biotech’s recent performance – and whether it can last – CLICK HERE.